Cognition Therapeutics, Inc. CGTX · SEC Filings

14

Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identi...

Price0.6906

Market Cap65.62 M

Float85.85 M

CountryUS

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 8, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Cognition Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Nov 5, 2026

8-K

Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies

Oct 22, 2026

8-K

Cognition Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

Aug 6, 2026

8-K

Cognition Therapeutics Aligns with FDA on Pivotal Study Design for Zervimesine in DLB Psychosis

Jun 24, 2026

8-K

Cognition Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 18, 2026

8-K

Cognition Therapeutics Advances Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis

Jun 4, 2026

Prospectus

TYPE

HEADLINE

FILED AT

Registrations

TYPE

HEADLINE

FILED AT

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 27, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 27, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 26, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 26, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Dec 29, 2025

CORRESP

Form CORRESP - Correspondence

Dec 22, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Jan 9, 2024

CORRESP

Form CORRESP - Correspondence

Jan 4, 2024

LETTER

Form UPLOAD - SEC-generated letter

Jan 3, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

Jan 4, 2023